keywords CRIZOTINIB EGFR EPITHELIAL-MESENCHYMAL TRANSITION ERLOTINIB INHIBITORS KRAS-MUTANT Life Sciences & Biomedicine Oncology RESISTANCE SELUMETINIB Science & Technology